AIRLINK 74.75 Increased By ▲ 0.46 (0.62%)
BOP 4.95 No Change ▼ 0.00 (0%)
CNERGY 4.34 Decreased By ▼ -0.03 (-0.69%)
DFML 39.70 Increased By ▲ 0.90 (2.32%)
DGKC 85.79 Increased By ▲ 0.97 (1.14%)
FCCL 21.23 Increased By ▲ 0.02 (0.09%)
FFBL 34.15 Increased By ▲ 0.03 (0.09%)
FFL 9.65 Decreased By ▼ -0.05 (-0.52%)
GGL 10.42 No Change ▼ 0.00 (0%)
HBL 113.65 Increased By ▲ 0.65 (0.58%)
HUBC 137.10 Increased By ▲ 0.90 (0.66%)
HUMNL 11.54 Decreased By ▼ -0.36 (-3.03%)
KEL 4.80 Increased By ▲ 0.09 (1.91%)
KOSM 4.55 Increased By ▲ 0.11 (2.48%)
MLCF 37.66 Increased By ▲ 0.01 (0.03%)
OGDC 139.75 Increased By ▲ 3.55 (2.61%)
PAEL 25.45 Increased By ▲ 0.35 (1.39%)
PIAA 20.68 Increased By ▲ 1.44 (7.48%)
PIBTL 6.61 Decreased By ▼ -0.10 (-1.49%)
PPL 122.73 Increased By ▲ 0.63 (0.52%)
PRL 26.64 Decreased By ▼ -0.01 (-0.04%)
PTC 14.05 Increased By ▲ 0.12 (0.86%)
SEARL 58.09 Increased By ▲ 0.87 (1.52%)
SNGP 67.28 Decreased By ▼ -0.32 (-0.47%)
SSGC 10.29 Increased By ▲ 0.04 (0.39%)
TELE 8.43 Increased By ▲ 0.03 (0.36%)
TPLP 11.15 Increased By ▲ 0.02 (0.18%)
TRG 63.64 Increased By ▲ 0.83 (1.32%)
UNITY 26.62 Increased By ▲ 0.12 (0.45%)
WTL 1.45 Increased By ▲ 0.10 (7.41%)
BR100 7,842 Increased By 31.5 (0.4%)
BR30 25,366 Increased By 216.4 (0.86%)
KSE100 75,138 Increased By 181.3 (0.24%)
KSE30 24,164 Increased By 80.9 (0.34%)

A US pharmaceutical firm has identified a new subtype of the human immunodeficiency virus (HIV), and said the finding showed that cutting edge genome sequencing is helping researchers stay ahead of mutations.

The strain, HIV-1 Group M subtype L, has been recorded in three people from blood samples taken between the 1980s and 2001, all in the Democratic Republic of Congo, Abbott laboratories told AFP on Thursday.

To classify a new subtype, three cases must be discovered independently, according to guidelines issued in 2000.

Group M is the most prevalent form of the HIV-1 virus. Subtype L is now the 10th of this group and the first to be identified since the guidelines were issued.

Antiretroviral drugs, which today can reduce the viral load of an HIV carrier to the point at which the infection is both undetectable and cannot be transmitted further, have generally performed well against a variety of subtypes, according to research. But there is also some evidence of subtype differences in drug resistance.

"Since subtype L is part of the major group of HIV, Group M, I would expect current treatments to work with it," Mary Rodgers, a principal scientist and head of the Global Viral Surveillance Program at Abbott told AFP.

Copyright Agence France-Presse, 2019

Comments

Comments are closed.